Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prevymis (letermovir)
Pharma
Merck's Prevymis outdoes Roche's Valcyte in toxicity measure
In testing Merck's Prevymis against Roche’s Valcyte in kidney transplant recipients, Prevymis showed comparable efficacy and a better safety profile.
Kevin Dunleavy
Oct 24, 2022 10:45am
Merck antiviral drug Prevymis wins NICE over
May 30, 2019 12:06pm
Merck's new CMV med Prevymis set for launch at $19K-plus
Nov 9, 2017 11:09am
